US2011008393A1PendingUtilityA1

Nucleic acids and corresponding proteins entitled 58p1d12 useful in treatment and detection of cancer

48
Individually held — no corporate assignee on recordPriority: Aug 12, 1999Filed: Jul 14, 2010Published: Jan 13, 2011
Est. expiryAug 12, 2019(expired)· nominal 20-yr term from priority
Inventors:Steven B. KannerAya JakobovitsPia M. Challita-EidWangmao GeArthur B. Raitano
C07K 16/30C07K 14/7056A61K 38/00C12Q 1/6881C12Q 2600/158A01K 2217/05C07K 2317/73A61P 35/00A61K 2039/505C12Q 2600/136G01N 2500/04C12N 2799/026C12N 2799/027C12Q 2600/156G01N 33/57555G01N 33/575A61K 40/4202A61K 40/24A61K 40/19A61K 40/10A61K 2239/38A61K 39/00
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A novel gene 58P1D12 and its encoded protein, and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization.

Claims

exact text as granted — not AI-modified
1 . An isolated transcript variant of a 58P1D12 gene, wherein the transcript variant is transcribed from the 58P1D12 gene and encodes a protein comprising at least one amino acid substitution, addition or deletion relative to SEQ ID NO:12. 
     
     
         2 . The transcript variant of  claim 1 , wherein the transcript variant comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:4 or SEQ ID NO:8. 
     
     
         3 . The transcript variant of  claim 1 , wherein the transcript variant encodes a protein comprising the amino acid sequence selected from the group consisting of SEQ ID NO:13, or SEQ ID NO:14. 
     
     
         4 . A recombinant expression vector comprising a transcript variant, wherein the transcript variant is transcribed from the 58P1D12 gene and encodes a protein comprising at least one amino acid substitution, addition or deletion relative to SEQ ID NO:12. 
     
     
         5 . The recombinant expression vector of  claim 4 , wherein the transcript variant comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:4 or SEQ ID NO:8. 
     
     
         6 . The recombinant expression vector of  claim 4 , further comprising a nucleotide sequence encoding a selection marker. 
     
     
         7 . The recombinant expression vector of  claim 4 , further comprising at least one suitable regulatory sequence operably linked to the transcript variant. 
     
     
         8 . A host cell comprising a recombinant expression vector comprising a transcript variant, wherein the transcript variant is transcribed from the 58P1D12 gene and encodes a protein comprising at least one amino acid substitution, addition or deletion relative to SEQ ID NO:12. 
     
     
         9 . The host cell of clam  8 , wherein the transcript variant comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:4 or SEQ ID NO:8. 
     
     
         10 . The host cell of  claim 8 , wherein the host cell is a prokaryotic cell. 
     
     
         11 . The host cell of  claim 10 , wherein the prokaryotic cell is  E. coli.    
     
     
         12 . The host cell of  claim 8 , wherein the host cell is a eucaryotic cell. 
     
     
         13 . The host cell of  claim 12 , wherein the host cell is selected from the group consisting of a yeast cell, a plant cell and an animal cell. 
     
     
         14 . The host cell of  claim 13 , wherein the animal cell is a mammalian cell. 
     
     
         15 . The host cell of  claim 14 , wherein the mammalian cell is selected from the group consisting of COS cells, CHO cells, 293 cells, and 293T cells. 
     
     
         16 . An isolated protein encoded by a transcript variant of a 58P1D12 gene, wherein the transcript variant is transcribed from the 58P1D12 gene and encodes a protein comprising at least one amino acid substitution, addition or deletion relative to SEQ ID NO:12. 
     
     
         17 . The protein of  claim 16 , wherein the protein is encoded by a transcript comprising the nucleic acid sequence selected from the group consisting of SEQ ID NO:4, or SEQ ID NO:8. 
     
     
         18 . The protein of  claim 16 , wherein the protein comprises the amino acid sequence selected from the group consisting of SEQ ID NO:13, or SEQ ID NO:14. 
     
     
         19 . An isolated antibody or fragment thereof that specifically binds to the protein of  claim 16 . 
     
     
         20 . The antibody or fragment thereof of  claim 19 , wherein the antibody is monoclonal. 
     
     
         21 . The antibody or fragment thereof of  claim 19 , wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody. 
     
     
         22 . The antibody or fragment thereof of  claim 19 , wherein the antibody or fragment thereof is labeled with an agent. 
     
     
         23 . A method of inducing a mammalian immune response directed to a protein encoded by a transcript variant of a 58P1D12 gene, wherein the transcript variant is transcribed from the 58P1D12 gene and encodes a protein comprising at least one amino acid substitution, addition or deletion relative to SEQ ID NO:12, comprising:
 exposing cells of the immune system of a mammal to an immunogenic portion of   the protein comprising at least one amino acid substitution, addition or deletion relative to SEQ ID NO:12; or   the transcript variant, or a combination of both, whereby the mammalian immune response directed to the protein is induced.   
     
     
         24 . The method of  claim 23 , wherein the immunogenic portion comprises at least one T cell or at least one B cell epitope. 
     
     
         25 . The method of  claim 24 , whereby the immunogenic portion induces a B cell to generate antibodies that specifically bind to the protein. 
     
     
         26 . The method of  claim 24 , whereby the immunogenic portion activates a cytotoxic T cell (CTL) that kills an autologous cell that expresses the protein. 
     
     
         27 . The method of  claim 24 , wherein the T cell is a helper T cell (HTL), whereby the immunogenic portion activates an HTL that secretes cytokines that facilitate the cytotoxic activity of a CTL or the antibody producing activity of a B cell. 
     
     
         28 . The method of  claim 23 , wherein the immune response comprises production of an antibody that binds specifically to the protein. 
     
     
         29 . The method of  claim 23 , wherein the protein is encoded by a transcript variant comprising the nucleic acid sequence selected from the group consisting of SEQ ID NO:4, or SEQ ID NO:8. 
     
     
         30 . The method of  claim 23 , wherein the protein comprises the amino acid sequence selected from the group consisting of SEQ ID NO:13, or SEQ ID NO:14. 
     
     
         31 . An immunogenic composition comprising an immunogenic portion of:
 a protein encoded by a transcript variant of a 58P1D12 gene, wherein the transcript variant is transcribed from the 58P1D12 gene and encodes a protein comprising at least one amino acid substitution, addition or deletion relative to SEQ ID NO:12; and/or   transcript variant that encodes the protein.   
     
     
         32 . The immunogenic composition of  claim 31 , wherein the protein is encoded by a transcript variant comprising the nucleic acid sequence selected from the group consisting of SEQ ID NO:4, or SEQ ID NO:8. 
     
     
         33 . The immunogenic composition of  claim 31 , wherein the protein comprises the amino acid sequence selected from the group consisting of SEQ ID NO:13, or SEQ ID NO:14. 
     
     
         34 . The immunogenic composition of  claim 31 , further comprising a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2011008393A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.